It is estimated that 38% of patients are considered to be GINA Step 3 of the Global Initiative for Asthma (GINA) stepwise approach to asthma treatment, and 41% of patients are considered to be at Step 4 or 5 [Adelphi Disease Specific Programme (DSP) 2018]. Despite the availability of standard-of-care asthma treatments, 35% of GINA 3 patients and over 50% of patients at GINA Step 4 and 5, respectively, remain uncontrolled (i.e. symptomatic and experience exacerbations).
To help overcome this and optimise your asthma management find out about the key inflammatory mediators involved, the therapeutic targets and information from the latest Global Initiative for Asthma (GINA), global strategy for asthma management and prevention report 2019, (which should be used in conjunction with other local/national guideline recommendations).
The content hosted on this platform is intended for non-promotional scientific purposes only. Developed by EPG Health for Medthority in collaboration with Novartis Pharma AG, with some content provided by Novartis Pharma AG (with the exception of the 2019 ERS Daily Blog content & ERS expert opinion videos which have been created independently and with no input from the sponsor). Date of preparation: September 2019 (GLRESP/RESP/0337)